| Product Unit Size | Cost | Quantity | Stock |
|---|
Fidaxomicin is a macrocyclic antibiotic, isolated from actinomycete Dactylosporangium aurantiacum. Fidaxomicin is an RNA polymerase inhibitor that has a narrow antibiotic activity spectrum and is not readily absorbed into the blood circulatory system. This anti-bacterial agent is almost Clostridium difficile specific in the colon, and has minimal effect to the intestinal microbial flora.
| Cas No. | 873857-62-6 |
|---|---|
| Purity | ≥98% |
| Formula | C52H74Cl2O18 |
| Formula Wt. | 1058.05 |
| Chemical Name | [(2R,3S,4S,5S,6R)-6-[[(3E,5E,8S,9E,11S,12R,13E,15E,18S)-12-[(2R,3S,4R,5S)-3,4-dihydroxy-6,6-dimethyl-5-(2-methylpropanoyloxy)oxan-2-yl]oxy-11-ethyl-8-hydroxy-18-[(1R)-1-hydroxyethyl]-9,13,15-trimethyl-2-oxo-1-oxacyclooctadeca-3,5,9,13,15-pentaen-3-yl]methoxy]-4-hydroxy-5-methoxy-2-methyloxan-3-yl] 3,5-dichloro-2-ethyl-4,6-dihydroxybenzoate |
| IUPAC Name | [(2R,3S,4S,5S,6R)-6-[[(3E,5E,8S,9E,11S,12R,13E,15E,18S)-12-[(2R,3S,4R,5S)-3,4-dihydroxy-6,6-dimethyl-5-(2-methylpropanoyloxy)oxan-2-yl]oxy-11-ethyl-8-hydroxy-18-[(1R)-1-hydroxyethyl]-9,13,15-trimethyl-2-oxo-1-oxacyclooctadeca-3,5,9,13,15-pentaen-3-yl]methoxy]-4-hydroxy-5-methoxy-2-methyloxan-3-yl] 3,5-dichloro-2-ethyl-4,6-dihydroxybenzoate |
| Synonym | Clostomicin B1, Dificid, Dificlir, lipiarmicin lipiarmycin, lipiarmycin A3, tiacumicin B. |
| Solubility | Insoluble in water, soluble in CHCl3(10 mg/ml), methanol(10 mg/ml), DMSO(1mg/ml). |
| Appearance | White to offwhite powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Poxton IR. Fidaxomicin: a new macrocyclic, RNA polymerase-inhibiting antibiotic for the treatment of Clostridium difficile infections. Future Microbiol. 2010 ;5(4):539-48 doi: 10.2217/fmb.10.20.PMID: 20353295 Review.
Yuan J, Yu J, Huang Y, et al. Antibiotic fidaxomicin is an RdRp inhibitor as a potential new therapeutic agent against Zika virus. BMC Med. 2020 Jul 31;18(1):204. PMID: 32731873.
Koon H, Wang J, Mussatto, C, et al. Fidaxomicin and OP-1118 inhibit Clostridium difficile toxin A- and B- mediated inflammatory responses via inhibition of NF-kB activity. Antimicrob Agents Chemother. 2017 Dec 21;62(1):e01513-17. PMID: 29038278.
Dailler D, Dorst A, Schafle D, et al. Novel fidaxomicin antibiotics through site-selective catalysis. Communications Chamistry. 2021. 4:59.